The ACS has always been about advancing the science of surgery, and our journals are a core component of that mission. From our flagship journal of the ACS to our more targeted offerings, you'll find every issue here as soon as they're published.
Rezum demonstrated equivalent efficacy in 993 BPH patients with prostates >80 cc compared to 1,732 with smaller glands, with comparable IPSS, IPSS-QoL, and Qmax improvements. Large prostates demonstrated superior bladder emptying and lower retreatment rates (3.6% vs 7.2%), supporting expanded treatment eligibility beyond the current 80 cc limit.